Amarin Plc(NASDAQ) AMRN

Amarin Corporation plc is a pharmaceutical company focused on improving cardiovascular health. It is best known for its flagship product, Vascepa, a prescription medication used to reduce triglyceride levels and cardiovascular risk in specific patient populations. Headquartered in Ireland, Amarin operates in multiple international markets through partnerships and direct sales.

Products and Services

Vascepa: A prescription drug designed to lower triglyceride levels and reduce cardiovascular risk in adults, especially those already on statin therapy.

What Makes Amarin Corporation plc Special

Amarin stands out due to Vascepa's unique formulation, which has been clinically proven to reduce cardiovascular events. With approval in multiple countries, Vascepa is the first and only drug approved specifically as an adjunct to statins for this purpose.

Five Things You Need to Know

Vascepa's efficacy and safety were validated through the REDUCE-IT clinical trial, showing significant reduction in cardiovascular events.

Amarin has secured regulatory approvals for Vascepa in the U.S., Europe, and several other markets, positioning it as an international player.

The company is implementing an organizational restructuring to focus on new strategic priorities and reduce operational costs.

Amarin's robust patent portfolio helps protect Vascepa's market position despite the emergence of generics in some markets.

Amarin's strategy involves expanding international partnerships to increase market access and revenue potential globally.